Lack of selectivity in cytotoxic agents leads to off-target damage of healthy tissues. Establishing high selectivity reduces adverse side effects and increases the therapeutic window.

Viral mutations frequently render single-agent treatments ineffective. Increasing the barrier to resistance prevents therapeutic failure and extends drug efficacy.

Viral reservoirs and latent infections remain unreachable by standard therapies. Eliminating these reservoirs prevents disease recurrence and long-term cellular damage.

Uncontrolled insertion of viral DNA into host genomes leads to persistent infection and replication. Inhibiting this specific step prevents the establishment of a permanent viral reservoir.